Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/194390
Title: | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
Author: | Brasó Maristany, Fara Griguolo, Gaia Chic, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina |
Keywords: | Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
Issue Date: | Dec-2022 |
Publisher: | Oxford University Press |
Abstract: | In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1093/jnci/djac227 |
It is part of: | JNCI: Journal of The National Cancer Institute, 2022 |
URI: | http://hdl.handle.net/2445/194390 |
Related resource: | https://doi.org/10.1093/jnci/djac227 |
ISSN: | 0027-8874 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
731692.pdf | 1.6 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.